Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier. We now aim to improve survival further.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska University Hospital
• Collaborators: Azienda Ospedaliero, Universitaria Meyer; Baylor College of Medicine; Children's Hospital Medical Center, Cincinnati; Ehime University Graduate School of Medicine; Great Ormond Street Hospital for Children NHS Foundation Trust; Hospital de Cruces; Hospital JP Garrahan; Leiden University Medical Center; St. Anna Kinderkrebsforschung; Texas Children's Hospital; Universitätsklinikum Hamburg-Eppendorf
• Treatments: BB 1101; Cyclosporine; Cyclosporins; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Etoposide; Etoposide phosphate

Criteria

Inclusion Criteria:

• Patients who fulfil the diagnostic criteria of HLH.

Exclusion Criteria:

• Prior cytotoxic or cyclosporin treatment for HLH.